Singapore, Jan. 15 -- China-based startup ElpasBio Holdings, a leading clinical-stage biotechnology company focused on regenerative medicine, has entered into a collaboration agreement with Fosun Kairos for the commercialisation of ElpasBio's investigational allogeneic human adipose-derived mesenchymal stem cell (haMPC) therapy, lotazadromcel (trade name AlloJoin(R)) for the treatment of knee osteoarthritis (KOA) in Mainland China, Hong Kong SAR, and Macau SAR.

AlloJoin(R) is ElpasBio's core investigational, off-the-shelf stem cell product, developed entirely in-house based on its proprietary haMPC technology platform and protected by independent intellectual property rights. The therapy is being explored for its potential to provide saf...